|

Mid-day market update: Gold drops over 2%, Leap Therapeutics shares jump

Midway through trading Thursday, the Dow traded down 0.74% to 34,557.75 while the NASDAQ fell 0.67% to 15,060.25. The S&P also fell, dropping 0.79% to 4,445.34.

The U.S. has the highest number of coronavirus cases and deaths in the world, reporting a total of 41,539,100 cases with around 666,620 deaths. India confirmed a total of at least 33,347,320 cases and 443,920 deaths, while Brazil reported over 21,034,610 COVID-19 cases with 588,590 deaths. In total, there were at least 226,445,290 cases of COVID-19 worldwide with more than 4,661,150 deaths, according to data compiled by Johns Hopkins University.

Leading and Lagging Sectors

Consumer discretionary shares slipped by just 0.1% on Thursday. Meanwhile, top gainers in the sector included Tuesday Morning Corporation TUEM +undefined% (Get Free Alerts for TUEM), up 23% and Vinco Ventures, Inc. BBIG +undefined% (Get Free Alerts for BBIG) up 9%.

In trading on Thursday, materials shares tumbled 1.7%.

Top Headline

US retail sales increased 0.7% in August of 2021, following a revised 1.8% decline in July. Analysts were expecting for a 0.8% decline in retail trade.

Equities Trading UP

Leap Therapeutics, Inc. LPTX +undefined% shares shot up 23% to $2.3650 after the company announced updated data from the first-line cohort of the DisTinGuish Phase 2a trial evaluating DKN-01 combined with BeiGene’s tislelizumab and chemotherapy in gastric or gastroesophageal junction cancer (G/GEJ).

Shares of Tuesday Morning Corporation TUEM +undefined% (Get Free Alerts for TUEM) got a boost, shooting 24% to $2.1450 after a SEC filing showed CEO Fred Hand purchased 511,387 shares of the company's common stock at an average price of $1.76.

TMC the metals company Inc. TMC +undefined% shares were also up, gaining 26% to $12.58 amid increased retail investor interest in the stock on social media.

Equities Trading DOWN

Silverback Therapeutics, Inc. SBTX +24.06% shares tumbled 28% to $11.72. The company presented interim clinical results from a Phase 1/1b clinical study of SBT6050 as a monotherapy and in combination with Merck & Co's Keytruda in patients with advanced or metastatic HER2-expressing or amplified solid tumors.

Shares of Aerie Pharmaceuticals, Inc. AERI +23.79% were down 28% to $11.29 after the company announced topline results of its Phase 2b COMET-1 study evaluating AR-15512 (TRPM8 Agonist) ophthalmic solution for dry eye disease. The company said that the study failed to achieve statistical significance at pre-determined primary endpoints at Day 28.

MacroGenics, Inc. MGNX +26.66% was down, falling 24% to $20.84 as the company disclosed results from Cohort A Part 1 of the Phase 2/3 MAHOGANY clinical trial of margetuximab.

Commodities

In commodity news, oil traded down 1% to $71.87, while gold traded down 2.3% to $1,752.80.

Silver traded down 4.8% Thursday to $22.65 while copper fell 2.7% to $4.2890.

Euro zone

European shares were higher today. The eurozone’s STOXX 600 gained 0.6%, the Spanish Ibex Index rose 1.18% and the German DAX 30 gained 0.49%. Meanwhile, the London’s FTSE 100 rose 0.31%, French CAC 40 climbed 0.81% and Italy’s FTSE MIB jumped 0.99%.

The Eurozone trade surplus shrank to EUR 20.7 billion in July from EUR 26.8 billion in the year-ago period, while passenger car registrations in the European Union dropped 19.1% year-over-year to 623 thousand units in August. Italy’s trade surplus narrowed to EUR 8.762 billion in July from EUR 9.689 billion in the year-ago month.

Economics

US initial jobless claims increased to 332 thousand in the week ending September 11 versus a reading of 312 thousand in the previous week.

The Philadelphia Fed manufacturing index climbed to 30.7 in September from 19.4 in August.

Retail sales increased 0.7% in August of 2021, following a revised 1.8% decline in July.

US business inventories rose 0.5% for July.

US natural-gas supplies surged 83 billion cubic feet last week, the Energy Information Administration said.

The Treasury International Capital report for July will be released at 4:00 p.m. ET.

Author

Benzinga Team

Benzinga's news desk is a dynamic and innovative team that provides real-time, actionable articles that help readers navigate the market.

More from Benzinga Team
Share:

Editor's Picks

EUR/USD meets initial support around 1.1800

EUR/USD remains on the back foot, although it has managed to reverse the initial strong pullback toward the 1.1800 region and regain some balance, hovering around the 1.1850 zone as the NA session draws to a close on Tuesday. Moving forward, market participants will now shift their attention to the release of the FOMC Minutes and US hard data on Wednesday.
 

GBP/USD bounces off lows, retargets 1.3550

After bottoming out just below the 1.3500 yardstick, GBP/USD now gathers some fresh bids and advances to the 1.3530-1.3540 band in the latter part of Tuesday’s session. Cable’s recovery comes as the Greenback surrenders part of its advance, although it keeps the bullish bias well in place for the day.

Gold remains offered below $5,000

Gold stays on the defensive on Tuesday, receding to the sub-$5,000 region per troy ounce on the back of the persistent move higher in the Greenback. The precious metal’s decline is also underpinned by the modest uptick in US Treasury yields across the spectrum.

RBNZ set to pause interest-rate easing cycle as new Governor Breman faces firm inflation

The Reserve Bank of New Zealand remains on track to maintain the Official Cash Rate at 2.25% after concluding its first monetary policy meeting of this year on Wednesday.

UK jobs market weakens, bolstering rate cut hopes

In the UK, the latest jobs report made for difficult reading. Nonetheless, this represents yet another reminder for the Bank of England that they need to act swiftly given the collapse in inflation expected over the coming months. 

Ripple slides to $1.45 as downside risks surge

Ripple edges lower at the time of writing on Tuesday, from the daily open of $1.48, as headwinds persist across the crypto market. A short-term support is emerging at $1.45, but a buildup of bearish positions could further weaken the derivatives market and prolong the correction.